Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Florian Heitz

Showing results (121-130 of 178) with videos related to

Pageof 18
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 18, 2024
Atezolizumab Combined With Platinum and Maintenance Niraparib for Recurrent Ovarian Cancer With a Platinum-Free Interval >6 Months: ENGOT-OV41/GEICO 69-O/ANITA Phase III TrialAntonio González-Martín, María Jesús Rubio, Florian Heitz, et al.
Gynecologic Oncology|July 1, 2026
Updated patient-reported outcomes and the effect of disease progression on health-related quality of life in the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancerMark S Shahin, Domenica Lorusso, Floor J Backes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 2, 2020
Endometrial Cancer Molecular Risk Stratification is Equally Prognostic for Endometrioid Ovarian CarcinomaPauline Krämer, Aline Talhouk, Mary Anne Brett, et al.
Gynecologic Oncology|August 7, 2013
ABCB1 (MDR1) polymorphisms and ovarian cancer progression and survival: a comprehensive analysis from the Ovarian Cancer Association Consortium and The Cancer Genome AtlasSharon E Johnatty, Jonathan Beesley, Bo Gao, et al.
Gynecologic Oncology|May 6, 2026
Lymph node involvement, surgery and adjuvant treatment in primary Endometrioid Ovarian carcinoma PAtients with eaRly-stage Disease (LEOPARD) - a multinational team initiativeMarcel Grube, Bianca Ribeiro de Souza, Andrea Neilson, et al.
Journal of the National Cancer Institute|June 25, 2014
ABCA transporter gene expression and poor outcome in epithelial ovarian cancerEllen L Hedditch, Bo Gao, Amanda J Russell, et al.
HGG Advances|July 28, 2021
Pleiotropy-guided transcriptome imputation from normal and tumor tissues identifies candidate susceptibility genes for breast and ovarian cancerSiddhartha P Kar, Daniel P C Considine, Jonathan P Tyrer, et al.
Oncotarget|October 15, 2017
Analyses of germline variants associated with ovarian cancer survival identify functional candidates at the 1q22 and 19p12 outcome lociDylan M Glubb, Sharon E Johnatty, Michael C J Quinn, et al.
NPJ Genomic Medicine|March 5, 2024
Genome-wide association analyses of ovarian cancer patients undergoing primary debulking surgery identify candidate genes for residual diseaseDhanya Ramachandran, Jonathan P Tyrer, Stefan Kommoss, et al.
Oncotarget|February 4, 2016
Germline polymorphisms in an enhancer of PSIP1 are associated with progression-free survival in epithelial ovarian cancerJuliet D French, Sharon E Johnatty, Yi Lu, et al.
Pageof 18

Showing results (121-130 of 178) with videos related to

Sort By:
Pageof 18
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 18, 2024
Atezolizumab Combined With Platinum and Maintenance Niraparib for Recurrent Ovarian Cancer With a Platinum-Free Interval >6 Months: ENGOT-OV41/GEICO 69-O/ANITA Phase III TrialAntonio González-Martín, María Jesús Rubio, Florian Heitz, et al.
Gynecologic Oncology|July 1, 2026
Updated patient-reported outcomes and the effect of disease progression on health-related quality of life in the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancerMark S Shahin, Domenica Lorusso, Floor J Backes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 2, 2020
Endometrial Cancer Molecular Risk Stratification is Equally Prognostic for Endometrioid Ovarian CarcinomaPauline Krämer, Aline Talhouk, Mary Anne Brett, et al.
Gynecologic Oncology|August 7, 2013
ABCB1 (MDR1) polymorphisms and ovarian cancer progression and survival: a comprehensive analysis from the Ovarian Cancer Association Consortium and The Cancer Genome AtlasSharon E Johnatty, Jonathan Beesley, Bo Gao, et al.
Gynecologic Oncology|May 6, 2026
Lymph node involvement, surgery and adjuvant treatment in primary Endometrioid Ovarian carcinoma PAtients with eaRly-stage Disease (LEOPARD) - a multinational team initiativeMarcel Grube, Bianca Ribeiro de Souza, Andrea Neilson, et al.
Journal of the National Cancer Institute|June 25, 2014
ABCA transporter gene expression and poor outcome in epithelial ovarian cancerEllen L Hedditch, Bo Gao, Amanda J Russell, et al.
HGG Advances|July 28, 2021
Pleiotropy-guided transcriptome imputation from normal and tumor tissues identifies candidate susceptibility genes for breast and ovarian cancerSiddhartha P Kar, Daniel P C Considine, Jonathan P Tyrer, et al.
Oncotarget|October 15, 2017
Analyses of germline variants associated with ovarian cancer survival identify functional candidates at the 1q22 and 19p12 outcome lociDylan M Glubb, Sharon E Johnatty, Michael C J Quinn, et al.
NPJ Genomic Medicine|March 5, 2024
Genome-wide association analyses of ovarian cancer patients undergoing primary debulking surgery identify candidate genes for residual diseaseDhanya Ramachandran, Jonathan P Tyrer, Stefan Kommoss, et al.
Oncotarget|February 4, 2016
Germline polymorphisms in an enhancer of PSIP1 are associated with progression-free survival in epithelial ovarian cancerJuliet D French, Sharon E Johnatty, Yi Lu, et al.
Pageof 18